Pharmacologic treatment of hypertensive disorders in pregnancy

 

Table 6: Recommendations related to treatment of hypertension and seizures in pregnancy issued by the Canadian Hypertension Society (CHS) and other international bodies*
Category CHS NHBPEPWG99 ASSH100

Nonsevere hypertension

BP readings at which to start treatment, mm Hg SBP > 139 or 149 or
DBP > 89 or 94
DBP > 99 SBP > 159 or
DBP > 89
Treatment goal, mm Hg DBP 80-90 -- SBP > 110
Drugs Methyldopa, labetalol, pindolol, oxprenolol, nifedipine Methyldopa Methyldopa, labetalol, oxprenolol, clonidine
Drugs to avoid ACE† inhibitor, angiotensin II receptor antagonist ACE inhibitor ACE inhibitor, diuretics

Severe hypertension

BP readings at which to start treatment, mm Hg SBP > 169 or
DBP >109
DBP > 104 SBP > 169 or
DBP > 114
Drugs Hydralazine, labetalol, nifedipine Hydralazine Hydralazine, labetalol nifedipine, diazoxide

Seizures

Drugs for prophylaxis Magnesium sulfate Magnesium sulfate Magnesium sulfate, phenytoin
Drugs for treatment Magnesium sulfate Magnesium sulfate Diazepam intravenously

*NHBPEPWG = National High Blood Pressure Education Program Working Group (US), ASSH = Australasian Society for Study of Hypertension.
†ACE = angiotensin-converting enzyme.

[Return to text]


| CMAJ November 1, 1997 (vol 157, no 9) / JAMC le 1er novembre 1997 (vol 157, no 9) |

CMA Webspinners / Les fileurs du Web de l'AMC